** Shares of medtech firm Glaukos Corp GKOS.N rise 3.3% to $158 premarket
** Brokerage Mizuho upgrades rating on GKOS to "outperform" from "neutral", citing its "disruptive potential" in the US glaucoma market
** Also raises PT to $200 from $140; representing a 30.8% upside to the stock's last close
** Brokerage says it believes iDose has a "substantial lead" in the drug-device combo setting and can drive up to $7 in adjusted EPS by 2030
** iDose is a device that helps lower eye pressure in people with glaucoma, a disease that damages the optic nerve, by slowly releasing medicine
** Expects iDose sales to reach over $1 bln by 2029, driven by a "favorable US adoption cycle with expanded coverage over the next several years"
** Says iDose has a unique advantage over competing products, such as Abbvie's ABBV.N Durysta implant, due to its "reservoir design that allows for continuous drug elution up to 3 years"
** GKOS gained 94.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.